OCR Employee Success Stories

Former employees at OCR have landed exciting positions in law, investing, entrepreneurship and more. Here are a few of their stories. 

Richard Madonna
Vice President for Finance and Administration, Connecticut College

Richard A. Madonna, Jr. has served as Vice President for Finance and Administration at Connecticut College since April of 2016. Rich has over 20 years of experience as an entrepreneur and innovator in finance and operations in higher education and the private sector. Rich has previously spent almost 6 years at Union Theological Seminary in the City of New York and 11 years at Yale University in New Haven, CT. At Union Theological Seminary, he was responsible for all aspects of finance, human resources, facilities, auxiliary activities, and information technology. Rich managed the implementation of several new technology solutions to modernize operations and oversaw the campus development and renovation project. While at Yale University, he held a series of increasingly responsible positions in finance and administration and led many University-wide projects. Rich started his Yale career in Internal Auditing, and then became the Business Manager at the Divinity School, the Director of Finance at the Office of Cooperative Research and Technology Transfer, the Lead Administrator for the Office of the Vice President and General Counsel, and was responsible for the leadership of shared services for Finance and Administration in the Office of the President, Vice Presidents, and Investments. Rich is the co-founder of two incubators, The Yale Entrepreneurial Institute in New Haven and the Union Food Lab in Harlem. He is a certified public accountant with a B.S. degree from Quinnipiac University.

Kimberly Muller
Director of CU Innovations, University of Colorado, Anschutz Medical Campus

Kimberly joined the University of Colorado in June 2015 with more than 15 years of experience in intellectual property management, licensing, research partnerships with corporations, and the formation of venture capital-financed startup companies. Kimberly was formerly the Deputy Director of the Yale Entrepreneurial Institute (YEI), and Associate Director of New Ventures at Yale University in the Office of Cooperative Research. Yale’s Office of Cooperative Research has started more than 70 new ventures that have raised $5 billion in investor capital. Previously, Kimberly managed the intellectual property and licensing for Curagen Corporation (acquired by Celldex Therapeutics), and was co-founder of Arbor Fuel, a biofuel company that utilized recombinant microorganisms for the production of ethanol and butanol. Kimberly began her career in New York as a patent attorney for Chadbourne and Parke, LLP and Morgan & Finnegan, LLP where her practice focused on pharmaceutical patent litigation. Kimberly has a graduate degree in genetics from the University of Connecticut and earned her Juris Doctorate with honors from the University of Connecticut School of Law. She is licensed to practice law in both New York and Connecticut.

Jim Reddoch, PhD
Executive Vice President, Head of Research & Investments, Royalty Pharma

Dr. Reddoch joined Royalty Pharma in July 2008 after 12 years on Wall Street as a biotechnology analyst. With $18 billion in assets, Royalty Pharma is the largest dedicated healthcare fund in the world. At Royalty Pharma, Jim runs a team of 7 professionals tasked with sourcing and analyzing new investments. Prior to joining Royalty Pharma, Dr. Reddoch was Managing Director and Head of Healthcare Equity Research at Friedman Billings Ramsey. He previously worked at Bank of America and CIBC World Markets Corp (now Oppenheimer & Co). Dr. Reddoch holds a BA from Furman University and a PhD in biochemistry and molecular genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine in the lab of Peter Glazer MD PhD, and while at Yale worked in the Office of Cooperative Research.

Thomas Shrader
Managing Director, Stifel

Thomas Shrader joined Stifel in 2014. Based out of the New York office, Dr. Shrader is a Managing Director in the Healthcare sector, covering Biotechnology. His past awards include the Wall Street Journal’s Best on the Street Survey Award. Before joining Stifel, Dr. Shrader was the Director of Strategic Corporate Partnerships at Yale University and spent a decade as a sell-side analyst, principally at BMO Capital Markets and its predecessors. Dr. Shrader has also been an associate and assistant professor of biochemistry at the Albert Einstein College of Medicine (AECOM) where he directed a laboratory focused on infectious diseases drug target discovery. While at AECOM, he served as an external grant reviewer for the NIH, and was a member of the board of reviewers for a number of journals, including The Journal of Biological Chemistry, Trends in Microbiology, and Genes & Development. Dr. Shrader was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology, earned a PhD in Molecular Biophysics and Biochemistry from Yale University and a Bachelor of Arts and Sciences degree in Biophysics from The Johns Hopkins University.

Erika Smith
CEO, ReNetX Bio

Erika Smith is the CEO of ReNetX Bio which is developing new therapeutics to treat injury/damage to the central nervous system in conditions such as spinal cord injury, stroke, and glaucoma. She was formerly the Director of the Blavatnik Fund for Innovation at Yale, a $10 million grant from the Blavatnik Family Foundation that supports efforts to turn Yale faculty discoveries into life science treatments, drugs and devices. Prior to this role, Erika was the Deputy Director of the Yale Entrepreneurial Institute where she oversaw the YEI Innovation Fund, a fund supporting Yale entrepreneurs with $100,000 in seed-stage capital, and the Technology Commercialization Program, which matched business students with faculty discoveries to launch successful companies like GestVision and IsoPlexis. Before she came to Yale, Erika was the Senior Director of Investments with the Center for Innovative Technologies (CIT) where she launched the CIT BIO Lifescience seed fund in partnership with Johnson & Johnson, managing deal sourcing and the investment portfolio. Before investing in startups, she spent 15 years in industry working at leading companies such as Respironics/Philips and IVAX holding key positions in product development, quality assurance, regulatory affairs, business development and Mergers and Acquisitions. She has taken an active role in advancing capital into early companies holding board positions with the Maryland Innovation Initiative Fund in partnership with Johns Hopkins and MD Universities, the UConn Prototype Fund and SBIR/STTR initiatives, and is a Venture Advisor to the seed fund Epidarex Capital. Erika has taught at the National Institutes of Health and has been a recognized guest speaker at Georgetown University’s Masters of Biotechnology program. She holds a bachelor’s in Biomedical and Electrical Engineering and a Masters of Business Administration from Vanderbilt University.

John Swartley
Associate Vice Provost for Research and Executive Director of the Penn Center for Innovation at the University of Pennsylvania

John S. Swartley, MBA, PhD is the Associate Vice Provost for Research and Executive Director of the Penn Center for Innovation (PCI) at the University of Pennsylvania (Penn), where he leads a team that is focused on facilitating new product development, venture creation and corporate partnerships based on expertise and technologies created at Penn.  Prior to joining Penn in 2007, Dr. Swartley served as Senior Vice President and General Partner of BCM Technologies (BCMT), the venture capital investment subsidiary of Baylor College of Medicine.  Dr. Swartley joined BCMT in 2003 from the Yale University Office of Cooperative Research where he was Associate Director of the Medical Campus Office. Over his career, Dr. Swartley has negotiated hundreds of commercialization and research partnership agreements and has participated in the formation and oversight of dozens of university spin-out companies that have collectively raised more than a billion dollars of investment capital. He holds a B.S. in Biology from Bates College, an MBA from the Goizueta School of Business at Emory University, and a PhD in Microbial & Molecular Genetics from Emory University.